Cellosaurus cell line NCI-H3122-CHR-A1 (CVCL

Cross-references
Cell line name	NCI-H3122-CHR-A1
Synonyms	H3122-CHR-A1; H3122 CHR-A1
Accession	CVCL_4Y37
Resource Identification Initiative	To cite this cell line use: NCI-H3122-CHR-A1 (RRID:CVCL_4Y37)
Comments	Population: Caucasian. Selected for resistance to: ChEBI; CHEBI_62268; Alectinib (CH5424802; RO5424802; AF-802). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations	Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (from parent cell line).
Disease	Lung adenocarcinoma (NCIt: C3512)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_5160 (NCI-H3122)
Sex of cell	Male
Age at sampling	54Y
Category	Cancer cell line
Publications	PubMed=25228534; DOI=10.1158/1078-0432.CCR-14-1511; PMCID=PMC4233168 Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin Franklin Gainor, Anthony John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita ...Show all 13 authors... , Jeffrey Adam Engelman, Alice Tsang Shaw; Show fewer authors Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20:5686-5696(2014)
Encyclopedic resources	Wikidata; Q54872052
Polymorphism and mutation databases	Cosmic; 2245572
Entry history
Entry creation	14-Dec-2015
Last entry update	19-Dec-2024
Version number	9